Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Patent
• Report
• Software

Filter by year:

Filter from 2024202320222021202020192018 to Filter to 2024202320222021202020192018

---

Search results

• Conference paper
  Zhao Y, Haddadi H, Skillman S, Enshaeifar S, Barnaghi Pet al., 2020,

  Privacy-preserving Activity and Health Monitoring on Databox

  , 3rd ACM International Workshop on Edge Systems, Analytics and Networking (EdgeSys), Publisher: ASSOC COMPUTING MACHINERY, Pages: 49-54
  • Author Web Link
  • Cite
  • Citations: 9
• Conference paper
  Enshaeifar S, Barnaghi P, Skillman S, Sharp D, Nilforooshan R, Rostill Het al., 2020,

  A Digital Platform for Remote Healthcare Monitoring

  , 29th World Wide Web Conference (WWW), Publisher: ASSOC COMPUTING MACHINERY, Pages: 203-206
  • Author Web Link
  • Cite
  • Citations: 5
• Conference paper
  Cavuto M, Hallam R, Rapeaux A, Maslik M, Troiani F, Constandinou Tet al., 2019,

  Live demonstration: a public engagement platform for invasive neural interfaces

  , IEEE Biomedical Circuits and Systems (BioCAS) Conference, Publisher: IEEE, Pages: 1-1

  Neural interfaces, and more specifically ones ofthe invasive/implantable variety, today are a topic of muchcontroversy, often making the general public uncomfortable andintimidated. We have thus devised a bespoke interactive demoto help people understand brain implants and their need inthe age of wearable devices, with the secondary objective ofintroducing the wireless cortical neural probe that we, at NGNI(Next Generation Neural Interfaces) lab, are developing.

  • Abstract
  • Publisher Web Link
  • Open Access Link
  • Cite
• Journal article
  Graham NSN, Sharp DJ, 2019,

  Understanding neurodegeneration after traumatic brain injury: from mechanisms to clinical trials in dementia

  , Journal of Neurology, Neurosurgery & Psychiatry, Vol: 90, ISSN: 0022-3050

  Traumatic brain injury (TBI) leads to increased rates of dementia, including Alzheimer’s disease. The mechanisms by which trauma can trigger neurodegeneration are increasingly understood. For example, diffuse axonal injury is implicated in disrupting microtubule function, providing the potential context for pathologies of tau and amyloid to develop. The neuropathology of post-traumatic dementias is increasingly well characterised, with recent work focusing on chronic traumatic encephalopathy (CTE). However, clinical diagnosis of post-traumatic dementia is problematic. It is often difficult to disentangle the direct effects of TBI from those produced by progressive neurodegeneration or other post-traumatic sequelae such as psychiatric impairment. CTE can only be confidently identified at postmortem and patients are often confused and anxious about the most likely cause of their post-traumatic problems. A new approach to the assessment of the long-term effects of TBI is needed. Accurate methods are available for the investigation of other neurodegenerative conditions. These should be systematically employed in TBI. MRI and positron emission tomography neuroimaging provide biomarkers of neurodegeneration which may be of particular use in the postinjury setting. Brain atrophy is a key measure of disease progression and can be used to accurately quantify neuronal loss. Fluid biomarkers such as neurofilament light can complement neuroimaging, representing sensitive potential methods to track neurodegenerative processes that develop after TBI. These biomarkers could characterise endophenotypes associated with distinct types of post-traumatic neurodegeneration. In addition, they might profitably be used in clinical trials of neuroprotective and disease-modifying treatments, improving trial design by providing precise and sensitive measures of neuronal loss.

  • Abstract
  • Publisher Web Link
  • Open Access Link
  • Cite
• Journal article
  Freemont P, 2019,

  Synthetic biology industry - Data-driven design is creating new opportunities in biotechnology.

  , Emerging Topics in Life Sciences, Vol: 3, Pages: 651-657, ISSN: 2397-8554

  Synthetic biology is a rapidly emerging interdisciplinary research field that is primarily built upon foundational advances in molecular biology combined with engineering design. The field considers living systems as programmable at the genetic level and has been defined by the development of new platform technologies. This has spurned a rapid growth in start-up companies and the new synthetic biology industry is growing rapidly, with start-up companies receiving ~$6.1B investment since 2015 and a global synthetic biology market value estimated to be $14B by 2026. Many of the new start-upscan be grouped within a multi-layer ‘technology stack’. The ‘stack’ comprises a number of technology layers which together can be applied to a diversity of new biotechnology applications like consumer biotechnology products and living therapies. The ‘stack’ also enables new commercial opportunities and value chains similar to the software design and manufacturing revolution of the 20th century. However, synthetic biology industry is at a crucial point, as it now requires recognisable commercial successes in order for the industry to expand and scale, in terms of investment and companies. However, such expansion may directly challenge the ethos of synthetic biology, in terms of open technology sharing and democratisation, which could by accident lead to multi-national corporations and technology monopolies similar to the existing biotechnology/biopharma industry.

  • Abstract
  • Publisher Web Link
  • Open Access Link
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.